MGMT and central nervous system cancer: In addition, the MGMT promoter methylation is a strong prognostic biomarker in patients with gliomas treated with TMZ, because the alkylating agent resistance of glioma cells is mainly mediated by MGMT, and epigenetic silencing of the MGMT gene by the promoter methylation compromises this DNA repair and increases chemotherapy sensitivity [37].